Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem-Cell Transplantation for De Novo ALL in Adults
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
— July 1, 2016
Read Article
Response-Adapted Sequential Azacitidine and Intensive Chemotherapy Is Effective in Patients Aged >60 Years with Newly Diagnosed AML
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
— July 1, 2016
Read Article
Valuable New Prognostic Scoring System in Patients with CML Receiving Nilotinib as Initial Treatment
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
— July 1, 2016
Read Article
Venetoclax Is Safe and Effective When Combined with Rituximab in Relapsed CLL
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
— July 1, 2016
Read Article
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Page 21 of 44
18
19
20
21
22
23
24
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma